Low-molecular-weight heparins in acute unstable coronary artery disease - an update.

Haemostasis Pub Date : 1999-12-01 DOI:10.1159/000054116
A G Turpie
{"title":"Low-molecular-weight heparins in acute unstable coronary artery disease - an update.","authors":"A G Turpie","doi":"10.1159/000054116","DOIUrl":null,"url":null,"abstract":"<p><p>Low-molecular-weight heparins (LMWHs) have been rigorously evaluated in the management of acute coronary ischaemia. The results of clinical trials suggest that the LMWHs (enoxaparin, dalteparin and nadroparin) are effective and safe in the treatment of unstable angina and non-Q-wave myocardial infarction. Two studies have shown enoxaparin to be more effective than unfractionated heparin in this setting. Furthermore, the pharmacologic and pharmacokinetic characteristics of LMWHs result in them having practical and economic advantages. Data on the benefits of long-term therapy with LMWHs are conflicting.</p>","PeriodicalId":12910,"journal":{"name":"Haemostasis","volume":"29 Suppl S1 ","pages":"72-5"},"PeriodicalIF":0.0000,"publicationDate":"1999-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000054116","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haemostasis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000054116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Low-molecular-weight heparins (LMWHs) have been rigorously evaluated in the management of acute coronary ischaemia. The results of clinical trials suggest that the LMWHs (enoxaparin, dalteparin and nadroparin) are effective and safe in the treatment of unstable angina and non-Q-wave myocardial infarction. Two studies have shown enoxaparin to be more effective than unfractionated heparin in this setting. Furthermore, the pharmacologic and pharmacokinetic characteristics of LMWHs result in them having practical and economic advantages. Data on the benefits of long-term therapy with LMWHs are conflicting.

低分子肝素在急性不稳定冠状动脉疾病中的作用
低分子肝素(LMWHs)在急性冠状动脉缺血的治疗中得到了严格的评价。临床试验结果表明,低分子肝素(依诺肝素、达尔特帕林和纳罗帕林)治疗不稳定型心绞痛和非q波型心肌梗死是有效和安全的。两项研究表明,在这种情况下,依诺肝素比未分离肝素更有效。此外,低分子肝素的药理学和药代动力学特性使其具有实用和经济优势。关于低分子白细胞长期治疗的益处的数据是相互矛盾的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信